These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 25424801)

  • 21. Strong HCV NS3/4a, NS4b, NS5a, NS5b-specific cellular immune responses induced in Rhesus macaques by a novel HCV genotype 1a/1b consensus DNA vaccine.
    Latimer B; Toporovski R; Yan J; Pankhong P; Morrow MP; Khan AS; Sardesai NY; Welles SL; Jacobson JM; Weiner DB; Kutzler MA
    Hum Vaccin Immunother; 2014; 10(8):2357-65. PubMed ID: 25424943
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Advances in hepatitis C virus vaccines, part two: advances in hepatitis C virus vaccine formulations and modalities.
    Roohvand F; Kossari N
    Expert Opin Ther Pat; 2012 Apr; 22(4):391-415. PubMed ID: 22455502
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Progress in the development of preventive and therapeutic vaccines for hepatitis C virus.
    Torresi J; Johnson D; Wedemeyer H
    J Hepatol; 2011 Jun; 54(6):1273-85. PubMed ID: 21236312
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vaccine prospects against hepatitis C.
    Roingeard P
    Bull Acad Natl Med; 2016 Jan; 200(1):59-65. PubMed ID: 29889413
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Recent trends in the therapy of hepatitis C].
    Meschini A; Lucchetta MC; Fontana M; Nocchi S; Pace A; Grassi M
    Clin Ter; 2003; 154(3):181-91. PubMed ID: 12910808
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Frequency, Private Specificity, and Cross-Reactivity of Preexisting Hepatitis C Virus (HCV)-Specific CD8+ T Cells in HCV-Seronegative Individuals: Implications for Vaccine Responses.
    Zhang S; Bakshi RK; Suneetha PV; Fytili P; Antunes DA; Vieira GF; Jacobs R; Klade CS; Manns MP; Kraft AR; Wedemeyer H; Schlaphoff V; Cornberg M
    J Virol; 2015 Aug; 89(16):8304-17. PubMed ID: 26041301
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 2011 European Association of the Study of the Liver hepatitis C virus clinical practice guidelines.
    European Association of the Study of the Liver
    Liver Int; 2012 Feb; 32 Suppl 1():2-8. PubMed ID: 22212565
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Challenges for development of hepatitis C virus vaccines.
    Prince AM
    FEMS Microbiol Rev; 1994 Jul; 14(3):273-7. PubMed ID: 8086198
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ledipasvir + sofosbuvir (Harvoni). A therapeutic advance in genotype 1 hepatitis C virus infection, despite uncertainties.
    Prescrire Int; 2015 Dec; 24(166):285-9. PubMed ID: 26788571
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Development of the novel oral vaccine against hepatitis C virus utilizing bifidobacteria].
    Shirakawa T
    Nihon Rinsho; 2015 Feb; 73(2):239-42. PubMed ID: 25764677
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hepatitis C: therapeutic perspectives.
    Cornberg M; Wedemeyer H; Manns MP
    Forum (Genova); 2001; 11(2):154-62. PubMed ID: 11948360
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Consensus guidelines for the management of hepatitis C infection.
    Consensus Guidelines Committee for the Management of Hepatitis C Infection
    Saudi Med J; 2003 Jul; 24 Suppl 2():S99-118. PubMed ID: 25121186
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Toward DNA-Based T-Cell Mediated Vaccines to Target HIV-1 and Hepatitis C Virus: Approaches to Elicit Localized Immunity for Protection.
    Mekonnen ZA; Grubor-Bauk B; Masavuli MG; Shrestha AC; Ranasinghe C; Bull RA; Lloyd AR; Gowans EJ; Wijesundara DK
    Front Cell Infect Microbiol; 2019; 9():91. PubMed ID: 31001491
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Distinct hepatitis C virus kinetics in HIV-infected patients treated with ribavirin plus either pegylated interferon alpha2a or alpha2b.
    Vispo E; Barreiro P; Rodriguez-Nóvoa S; Morello J; Labarga P; Martín-Carbonero L; Maida I; García-Gascó P; Soriano V
    Antivir Ther; 2008; 13(4):511-7. PubMed ID: 18672529
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immune responses against hepatitis C virus genotype 3a virus-like particles in mice: A novel VLP prime-adenovirus boost strategy.
    Kumar A; Das S; Mullick R; Lahiri P; Tatineni R; Goswami D; Bhat P; Torresi J; Gowans EJ; Karande AA; Das S
    Vaccine; 2016 Feb; 34(8):1115-25. PubMed ID: 26700891
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Capitalizing on knowledge of hepatitis C virus neutralizing epitopes for rational vaccine design.
    Kong L; Jackson KN; Wilson IA; Law M
    Curr Opin Virol; 2015 Apr; 11():148-57. PubMed ID: 25932568
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Complete definition of immunological correlates of protection and clearance of hepatitis C virus infection: a relevant pending task for vaccine development.
    Alvarez-Lajonchere L; Dueñas-Carrera S
    Int Rev Immunol; 2012 Jun; 31(3):223-42. PubMed ID: 22587022
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses.
    Liu CJ; Chuang WL; Lee CM; Yu ML; Lu SN; Wu SS; Liao LY; Chen CL; Kuo HT; Chao YC; Tung SY; Yang SS; Kao JH; Liu CH; Su WW; Lin CL; Jeng YM; Chen PJ; Chen DS
    Gastroenterology; 2009 Feb; 136(2):496-504.e3. PubMed ID: 19084016
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Hepatitis C--treatment of untreated (naive) patients].
    Duvnjak M; Pavić T; Tomasić V; Lerotić I; Virović L
    Acta Med Croatica; 2005; 59(5):453-61. PubMed ID: 16381243
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dynamic evolution of therapy for chronic hepatitis C: how will novel agents be incorporated into the standard of care?
    Zeuzem S; Nelson DR; Marcellin P
    Antivir Ther; 2008; 13(6):747-60. PubMed ID: 18839776
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.